Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -995.54 Thousand AUD | 67.73% |
| 2023 | -3.08 Million AUD | 66.14% |
| 2022 | -15.2 Million AUD | -48.43% |
| 2021 | -10.33 Million AUD | -13.57% |
| 2020 | -5.18 Million AUD | -9.2% |
| 2019 | -4.83 Million AUD | -4559.0% |
| 2018 | 448.28 Thousand AUD | -62.73% |
| 2017 | 383.44 Thousand AUD | 106.98% |
| 2016 | -4.41 Million AUD | -144.52% |
| 2015 | -4.13 Million AUD | 22.82% |
| 2014 | -4.56 Million AUD | 19.43% |
| 2013 | -4.93 Million AUD | 0.0% |
| 2010 | -5.98 Million AUD | 42.11% |
| 2009 | -11.19 Million AUD | -118.09% |
| 2008 | -3 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -199.86 Thousand AUD | 49.79% |
| 2024 FY | - AUD | 69.49% |
| 2024 Q4 | -541.63 Thousand AUD | 0.0% |
| 2024 Q2 | -467.12 Thousand AUD | -133.72% |
| 2023 Q1 | -777.24 Thousand AUD | 91.59% |
| 2023 FY | - AUD | 66.14% |
| 2023 Q4 | -523.19 Thousand AUD | -167.61% |
| 2023 Q3 | -195.5 Thousand AUD | 93.27% |
| 2023 Q2 | -2.9 Million AUD | -274.02% |
| 2022 FY | - AUD | -48.43% |
| 2022 Q3 | -2.88 Million AUD | 54.45% |
| 2022 Q4 | -9.23 Million AUD | -220.04% |
| 2022 Q2 | -6.33 Million AUD | -217.57% |
| 2022 Q1 | -1.99 Million AUD | 69.94% |
| 2021 Q4 | -6.63 Million AUD | -223.57% |
| 2021 Q1 | -1.32 Million AUD | 53.93% |
| 2021 FY | - AUD | -13.57% |
| 2021 Q2 | -4.2 Million AUD | -216.49% |
| 2021 Q3 | -2.05 Million AUD | 51.19% |
| 2020 Q2 | -2.96 Million AUD | -264.16% |
| 2020 Q3 | -909.11 Thousand AUD | 69.38% |
| 2020 Q4 | -2.88 Million AUD | -217.11% |
| 2020 FY | - AUD | -9.2% |
| 2020 Q1 | -815.35 Thousand AUD | 72.77% |
| 2019 Q3 | -931.07 Thousand AUD | -111.61% |
| 2019 Q1 | -439.99 Thousand AUD | 1.23% |
| 2019 FY | - AUD | -4559.0% |
| 2019 Q2 | -439.99 Thousand AUD | -0.0% |
| 2019 Q4 | -2.99 Million AUD | -221.55% |
| 2018 Q2 | -386.3 Thousand AUD | -0.0% |
| 2018 Q1 | -386.3 Thousand AUD | -3.67% |
| 2018 FY | - AUD | -62.73% |
| 2018 Q4 | -445.45 Thousand AUD | 0.0% |
| 2018 Q3 | -445.45 Thousand AUD | -15.31% |
| 2017 Q2 | -405.05 Thousand AUD | 0.0% |
| 2017 Q4 | -372.61 Thousand AUD | 0.0% |
| 2017 Q3 | -372.61 Thousand AUD | 8.01% |
| 2017 FY | - AUD | 106.98% |
| 2017 Q1 | -405.05 Thousand AUD | 20.78% |
| 2016 Q2 | -415.66 Thousand AUD | 0.0% |
| 2016 FY | - AUD | -144.52% |
| 2016 Q1 | -415.66 Thousand AUD | -102.45% |
| 2016 Q4 | -511.31 Thousand AUD | 0.0% |
| 2016 Q3 | -511.31 Thousand AUD | -23.01% |
| 2015 Q2 | -729.22 Thousand AUD | 0.0% |
| 2015 Q1 | -729.22 Thousand AUD | -41.34% |
| 2015 FY | - AUD | 22.82% |
| 2015 Q4 | -205.32 Thousand AUD | 0.0% |
| 2015 Q3 | -205.32 Thousand AUD | 71.84% |
| 2014 Q4 | -515.95 Thousand AUD | 0.0% |
| 2014 Q3 | -515.95 Thousand AUD | 25.75% |
| 2014 Q2 | -694.84 Thousand AUD | -0.0% |
| 2014 Q1 | -694.84 Thousand AUD | -5.78% |
| 2014 FY | - AUD | 19.43% |
| 2013 Q2 | -845.97 Thousand AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q3 | -656.87 Thousand AUD | 22.35% |
| 2013 Q1 | -845.97 Thousand AUD | 0.0% |
| 2013 Q4 | -656.87 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 42.11% |
| 2009 FY | - AUD | -118.09% |
| 2008 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 81.226% |
| Acrux Limited | -7.93 Million AUD | 87.447% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 78.166% |
| Biome Australia Limited | -1.57 Million AUD | 36.921% |
| BTC Health Limited | 1.05 Million AUD | 194.339% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 91.19% |
| CSL Limited | 4.73 Billion AUD | 100.021% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 97.77% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 101.92% |
| Noxopharm Limited | -5.94 Million AUD | 83.255% |
| PharmAust Limited | -9.45 Million AUD | 89.467% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 87.378% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 86.145% |
| PYC Therapeutics Limited | -38.11 Million AUD | 97.388% |
| Race Oncology Limited | -14.2 Million AUD | 92.991% |
| Starpharma Holdings Limited | -12.57 Million AUD | 92.084% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 109.595% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 92.848% |
| Memphasys Limited | -3.3 Million AUD | 69.902% |
| Nyrada Inc. | -4.59 Million AUD | 78.34% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 31.656% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 104.335% |
| Bio-Gene Technology Limited | -2.97 Million AUD | 66.536% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 97.268% |
| Patrys Limited | -3.49 Million AUD | 71.492% |
| Dimerix Limited | -24.95 Million AUD | 96.011% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 100.5% |
| Orthocell Limited | -11.68 Million AUD | 91.477% |
| Imugene Limited | -147.97 Million AUD | 99.327% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 89.995% |
| Immutep Limited | -42.87 Million AUD | 97.678% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 88.729% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 94.913% |
| Nanollose Limited | -1.14 Million AUD | 13.273% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -38.185% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | 44.578% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | 64.673% |
| Biotron Limited | -5.04 Million AUD | 80.247% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 97.806% |
| Tissue Repair Ltd | -5.77 Million AUD | 82.761% |
| AnteoTech Limited | -11.57 Million AUD | 91.396% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 98.457% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 95.338% |
| Avecho Biotechnology Limited | -3.24 Million AUD | 69.297% |
| Actinogen Medical Limited | -12.92 Million AUD | 92.295% |
| Immuron Limited | -6.19 Million AUD | 83.923% |
| Argenica Therapeutics Limited | -1.89 Million AUD | 47.536% |